Latest Breaking News On - Davida walsey - Page 1 : vimarsana.com

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davida walseyDavid ursoRichard ghalieMei pharma incPharma incAcademic gi cancer consortiumClinical study protocolBevacizumab combinationInitial safetyInitial efficacyPrivate securities litigation reform act

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David ursoTaheer datooDavida walseyCompany board of directorsMei pharma incPharma incCable car capitalAnson fundsClinical studyPrivate securities litigation reform act

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesYesid alvarado valeroRichard ghalieDavida walseyDepartment of leukemiaUniversity of texas md anderson cancer centerSafety review committeePharma incMei pharma incAssociate professorCancer centerPlus venetoclax combinationInitial safetyInitial efficacyPrivate securities litigation reform act

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO (BUSINESS WIRE) MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corpor.

United statesDavidm ursoDavida walseyPharma incAmerican society of hematology annual meetingSecurities exchangeSecond quarter fiscal yearAmerican societyHematology annual meetingSix month fiscal yearKyowa kirin commercialization agreementSecurities actSecurities exchange actPrivate securities litigation reform actConsolidated statements

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davida walseyPatrickm bolandPharma incAcademic gi cancer consortiumOngoing phaseStudy evaluatingMetastatic colorectal cancerCombination intendedCreate metabolic synthetic lethalityCancers symposiumRefractory metastatic colorectal cancerPacific timePrivate securities litigation reform act